[go: up one dir, main page]

PE20110547A1 - Compuestos de isoindolina con actividad anticancerigena - Google Patents

Compuestos de isoindolina con actividad anticancerigena

Info

Publication number
PE20110547A1
PE20110547A1 PE2011000958A PE2011000958A PE20110547A1 PE 20110547 A1 PE20110547 A1 PE 20110547A1 PE 2011000958 A PE2011000958 A PE 2011000958A PE 2011000958 A PE2011000958 A PE 2011000958A PE 20110547 A1 PE20110547 A1 PE 20110547A1
Authority
PE
Peru
Prior art keywords
cancer activity
isoindoline compounds
compounds
isoindol
dioxo
Prior art date
Application number
PE2011000958A
Other languages
English (en)
Inventor
George W Muller
Alexander L Ruchelman
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PE20110547A1 publication Critical patent/PE20110547A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN DERIVADO DE ISOINDOLINA DE FORMULA (I), DONDE X ES C(=O) O CH2; Y ES O, CIANAMIDO O AMIDO; m ES UN ENTERO DE 0 A 3; R1 ES H O ALQUILO C1-C6; R2 ES H, NO2, ALQUILO C0-C6-NH2, ENTRE OTROS; R3 ES H, HALOGENO, NO2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-[2-(2,6-DIOXO-PIPERIDIN-3-IL)-1-OXO-2,3-DIHIDRO-1H-ISOINDOL-5-ILMETIL]-3-(4-PIRIDIN-4-ILMETIL-FENIL)-UREA, 1-[2-(2,6-DIOXO-PIPERIDIN-3-IL)-1-OXO-2,3-DIHIDRO-1H-ISOINDOL-5-ILMETIL-3-(4-HIDROXIMETIL-FENIL)-UREA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2011000958A 2008-10-29 2009-10-26 Compuestos de isoindolina con actividad anticancerigena PE20110547A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10947508P 2008-10-29 2008-10-29

Publications (1)

Publication Number Publication Date
PE20110547A1 true PE20110547A1 (es) 2011-08-04

Family

ID=41328433

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011000958A PE20110547A1 (es) 2008-10-29 2009-10-26 Compuestos de isoindolina con actividad anticancerigena
PE2014000149A PE20140963A1 (es) 2008-10-29 2009-10-26 Compuestos de isoindolina para el tratamiento de cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000149A PE20140963A1 (es) 2008-10-29 2009-10-26 Compuestos de isoindolina para el tratamiento de cancer

Country Status (30)

Country Link
US (6) US8129375B2 (es)
EP (3) EP2985281B1 (es)
JP (3) JP5603876B2 (es)
KR (3) KR101696938B1 (es)
CN (2) CN104744434A (es)
AR (6) AR074001A1 (es)
AU (1) AU2009311477B2 (es)
BR (1) BRPI0919942B1 (es)
CA (2) CA2957226C (es)
CL (1) CL2011000957A1 (es)
CO (1) CO6361916A2 (es)
DK (1) DK2358697T3 (es)
ES (2) ES2559388T3 (es)
HR (1) HRP20151366T1 (es)
HU (1) HUE026105T2 (es)
IL (9) IL212435A (es)
MX (2) MX2011004470A (es)
NI (1) NI201100082A (es)
NZ (1) NZ592425A (es)
PE (2) PE20110547A1 (es)
PL (1) PL2358697T3 (es)
PT (1) PT2358697E (es)
RU (1) RU2527952C2 (es)
SG (2) SG10201703508QA (es)
SI (1) SI2358697T1 (es)
SM (1) SMT201600025B (es)
TW (1) TWI469974B (es)
UA (1) UA107783C2 (es)
WO (1) WO2010053732A1 (es)
ZA (1) ZA201102941B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
KR102223060B1 (ko) 2013-04-17 2021-03-05 시그날 파마소티칼 엘엘씨 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법
ES2903155T3 (es) 2013-12-06 2022-03-31 Celgene Corp Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células B grandes, mieloma múltiple y cánceres mieloides
WO2015160845A2 (en) * 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EA201790439A1 (ru) 2014-08-22 2017-07-31 Селджин Корпорейшн Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
JP2017538104A (ja) * 2014-10-07 2017-12-21 セルジーン コーポレイション 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用
EP3643709B1 (en) * 2014-10-30 2021-10-20 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
BR112017015497A2 (pt) 2015-01-20 2018-01-30 Arvinas, Inc. composto, e, composição
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CA3010797C (en) 2016-01-08 2024-01-02 Celgene Corporation Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
LT3399978T (lt) 2016-01-08 2021-05-10 Celgene Corporation Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas
ES2959267T3 (es) * 2016-01-08 2024-02-22 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
CA3010801A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CA3020541A1 (en) * 2016-04-12 2017-10-19 The Regents Of The University Of Michigan Bet protein degraders
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
KR20250044800A (ko) * 2016-10-11 2025-04-01 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
AU2017382436C1 (en) 2016-12-23 2021-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
WO2018144649A1 (en) 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
ES2902052T3 (es) 2017-02-28 2022-03-24 Kangpu Biopharmaceuticals Ltd Nuevo derivado de isoindolina, y composición farmacéutica y aplicación del mismo
US10406165B2 (en) 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN112312904B (zh) 2018-04-16 2025-01-07 C4医药公司 螺环化合物
WO2019209692A1 (en) 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
CA3101174A1 (en) 2018-05-23 2019-11-28 Celgene Corporation Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
RU2695326C1 (ru) * 2018-06-05 2019-07-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Противоопухолевое средство для лечения рака предстательной железы в форме саше
CN112638380B (zh) * 2018-06-29 2024-05-24 达纳-法伯癌症研究所有限公司 小脑蛋白(crbn)配体
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
HRP20231295T1 (hr) 2018-07-10 2024-02-02 Novartis Ag Derivati 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba u liječenju bolesti ovisnih o cinkovom prstu 2 (ikzf2) obitelji ikaros
KR102277626B1 (ko) * 2018-08-16 2021-07-15 한국화학연구원 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
JP7709378B2 (ja) * 2018-12-03 2025-07-16 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
US20220041578A1 (en) 2018-12-06 2022-02-10 Shanghai Institute Of Meteria Medica, Chinese Academy Of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
EP3935050B1 (en) 2019-03-06 2024-10-02 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
MA55628A (fr) 2019-04-12 2022-02-16 C4 Therapeutics Inc Agents de dégradation tricycliques d'ikaros et d'aiolos
US11564913B2 (en) 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN114466839B (zh) 2019-05-31 2025-01-07 医肯纳肿瘤学公司 Tead抑制剂和其用途
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
JP7724394B2 (ja) * 2019-10-09 2025-08-18 モンテ ローザ セラピューティクス アーゲー イソインドリノン化合物
CA3154386A1 (en) 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
US12280096B2 (en) 2021-07-12 2025-04-22 Penland Foundation Treatments of cancer using nitrous oxide and botulinum toxin
WO2021086829A1 (en) * 2019-10-28 2021-05-06 Celgene Corporation Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies
CN119039271A (zh) * 2019-12-17 2024-11-29 奥里尼斯生物科学股份有限公司 调节蛋白质募集和/或降解的化合物
CR20220353A (es) 2019-12-19 2022-10-20 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
KR20230051120A (ko) * 2020-03-31 2023-04-17 오름테라퓨틱 주식회사 신규분해약물 접합체
JP2023524599A (ja) 2020-05-09 2023-06-12 アルビナス・オペレーションズ・インコーポレイテッド 二官能性化合物を製造する方法、二官能性化合物の超高純度形態、及びそれらを含む剤形
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
PE20231555A1 (es) 2020-09-14 2023-10-03 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos
KR102499522B1 (ko) 2020-09-23 2023-02-13 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
AU2022207648A1 (en) * 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN117242060A (zh) * 2021-01-13 2023-12-15 蒙特罗萨医疗公司 异吲哚啉酮化合物
WO2022200857A1 (en) * 2021-03-22 2022-09-29 Monte Rosa Therapeutics Ag Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
EP4323350A1 (en) * 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone compounds
AU2022259683A1 (en) 2021-04-16 2023-10-19 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
CN118055779A (zh) * 2021-06-03 2024-05-17 奥隆制药 新降解剂缀合物
TW202313022A (zh) * 2021-06-03 2023-04-01 南韓商歐倫醫療公司 新降解劑－抗ｃｄ３３抗體綴合物
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023037268A1 (en) * 2021-09-08 2023-03-16 Orum Therapeutics, Inc. Linkers for use in antibody drug conjugates
CN116082301A (zh) * 2021-11-05 2023-05-09 上海美志医药科技有限公司 具有降解gspt1活性的化合物及其应用
KR102823538B1 (ko) 2021-11-09 2025-06-23 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
EP4431505A4 (en) 2021-11-09 2025-09-24 Korea Res Inst Chemical Tech ISOINDOLINONE DERIVATIVE HAVING A GLUTARIMIDE MOTHER NUCLEUS AND ITS USE
US20250034107A1 (en) * 2021-11-23 2025-01-30 St. Jude Children's Research Hospital, Inc. Substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl) acetamide analogs as modulators of gspt1 and/or ikzf1 protein
JP2024546851A (ja) * 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
JP2025513877A (ja) * 2022-04-14 2025-04-30 ブリストル－マイヤーズ スクイブ カンパニー 新規なｇｓｐｔ１化合物およびその新規な化合物の使用方法
EP4527415A1 (en) * 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
AU2023283735A1 (en) 2022-06-06 2024-10-31 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
JP2025533132A (ja) * 2022-10-06 2025-10-03 オラム・セラピューティクス・インコーポレイテッド ｎｅｏＤｅｇｒａｄｅｒコンジュゲート
KR20240066906A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR20240066904A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
PE20252585A1 (es) * 2023-02-10 2025-11-11 Nanjing Huanbo Biotechnology Co Ltd Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos
AU2024223101A1 (en) * 2023-02-15 2025-09-04 CSPC Megalith Biopharmaceutical Co., Ltd. Domide molecular glue derivative and use thereof
WO2025016359A1 (zh) * 2023-07-14 2025-01-23 标新生物医药科技(上海)有限公司 戊二酰亚胺基异吲哚啉酮骨架的化合物
WO2025085416A1 (en) * 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
WO2026007898A1 (zh) * 2024-07-01 2026-01-08 上海海雁医药科技有限公司 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
JP3204972B2 (ja) * 1991-04-17 2001-09-04 グリューネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規サリドマイド誘導体、その製造方法並びにこれを薬剤として使用する方法
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
DE19613976C1 (de) 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
CA2560523C (en) 1996-07-24 2011-09-20 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CN100488959C (zh) 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP1755600A2 (en) 2004-04-23 2007-02-28 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
MX2007005570A (es) 2004-11-12 2007-07-09 Celgene Corp Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
BRPI0518282A2 (pt) 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
WO2006060507A2 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
CA2899923A1 (en) * 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
ES2485316T3 (es) 2005-09-01 2014-08-13 Celgene Corporation Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
ES2426350T3 (es) * 2006-08-30 2013-10-22 Celgene Corporation Compuestos de isoindolina sustituidos en 5
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ATE502634T1 (de) * 2006-09-15 2011-04-15 Celgene Corp N-methylaminomethyl-isoindol-verbindungen und diese enthaltende zusammensetzungen und diese verwendende verfahren

Also Published As

Publication number Publication date
JP2015227343A (ja) 2015-12-17
IL234164A (en) 2016-07-31
JP2012507541A (ja) 2012-03-29
MX361467B (es) 2018-12-06
SI2358697T1 (sl) 2016-02-29
EP3354646A1 (en) 2018-08-01
JP5603876B2 (ja) 2014-10-08
WO2010053732A1 (en) 2010-05-14
ES2662407T3 (es) 2018-04-06
SMT201600025B (it) 2016-02-25
HUE026105T2 (en) 2016-05-30
NZ592425A (en) 2013-04-26
IL234163A (en) 2016-06-30
AR106942A2 (es) 2018-03-07
SG195613A1 (en) 2013-12-30
KR20170007531A (ko) 2017-01-18
CN104744434A (zh) 2015-07-01
JP2014224119A (ja) 2014-12-04
RU2527952C2 (ru) 2014-09-10
CL2011000957A1 (es) 2011-09-16
ZA201102941B (en) 2012-07-25
EP2358697A1 (en) 2011-08-24
AR106944A2 (es) 2018-03-07
US9227954B2 (en) 2016-01-05
IL234166B (en) 2018-04-30
US20170088538A1 (en) 2017-03-30
BRPI0919942B1 (pt) 2019-02-19
US20100204227A1 (en) 2010-08-12
KR101696938B1 (ko) 2017-01-16
CA2741299A1 (en) 2010-05-14
US20160115161A1 (en) 2016-04-28
US9550766B2 (en) 2017-01-24
US9796698B2 (en) 2017-10-24
AU2009311477A1 (en) 2010-05-14
US20120122865A1 (en) 2012-05-17
KR20110089162A (ko) 2011-08-04
TW201022227A (en) 2010-06-16
EP2985281A3 (en) 2016-03-30
RU2011121567A (ru) 2012-12-10
TWI469974B (zh) 2015-01-21
CA2957226A1 (en) 2010-05-14
PL2358697T3 (pl) 2016-04-29
IL234165A (en) 2017-08-31
US8318773B2 (en) 2012-11-27
PE20140963A1 (es) 2014-08-06
US8222249B2 (en) 2012-07-17
CN102264720A (zh) 2011-11-30
KR20180000750A (ko) 2018-01-03
CA2741299C (en) 2017-03-28
JP6034924B2 (ja) 2016-11-30
MX2011004470A (es) 2011-05-31
US20120252843A1 (en) 2012-10-04
CO6361916A2 (es) 2012-01-20
AR074001A1 (es) 2010-12-15
AR106963A2 (es) 2018-03-07
ES2559388T3 (es) 2016-02-11
IL212435A0 (en) 2011-06-30
EP2985281A2 (en) 2016-02-17
HRP20151366T1 (hr) 2016-01-15
US8129375B2 (en) 2012-03-06
IL228597A0 (en) 2013-12-31
PT2358697E (pt) 2016-02-03
SG10201703508QA (en) 2017-06-29
AU2009311477B2 (en) 2014-10-30
IL234168A (en) 2016-07-31
DK2358697T3 (en) 2016-01-25
IL234162A (en) 2016-06-30
US20130045976A1 (en) 2013-02-21
NI201100082A (es) 2011-10-26
AR106945A2 (es) 2018-03-07
BRPI0919942A2 (pt) 2014-12-23
CA2957226C (en) 2018-08-14
EP2985281B1 (en) 2017-12-27
AR106943A2 (es) 2018-03-07
IL212435A (en) 2015-06-30
CN102264720B (zh) 2015-03-25
JP5998179B2 (ja) 2016-09-28
EP2358697B1 (en) 2015-10-21
IL234167A (en) 2017-09-28
HK1154859A1 (zh) 2012-05-04
UA107783C2 (en) 2015-02-25
IL228597A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20090772A1 (es) Derivados de bencimidazol
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
EA201100037A1 (ru) Органические соединения
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20141120A1 (es) Compuestos heterociclicos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
EA201101084A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2011000979A1 (es) Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed